Physician profile
Karen Powers
NPI 1265640205
$1,650.39
in general payments reported to CMS, 2019-2025
22 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6.40 · 2021: $105 · 2022: $210 · 2023: $692 · 2024: $121 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.81 | 2022-2025 | |
| Ucb, INC. | $301.13 | 2022-2025 | Briviact, Fintepla |
| Sk Life Science, INC. | $198.97 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $98.08 | 2021-2024 | Jornay Pm |
| Catalyst Pharmaceuticals, INC. | $80.24 | 2023-2024 | Fycompa |
| Jazz Pharmaceuticals INC. | $73.88 | 2024-2025 | |
| Corium, LLC | $69.45 | 2023 | Azstarys, Azstarys |
| Eisai INC. | $50.42 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $48.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.42 | 2022 | |
| Lilly USA, LLC | $34.78 | 2025 | Emgality, Kisunla |
| Supernus Pharmaceuticals, INC. | $30.49 | 2023 | Qelbree |
| Biocodex, INC. | $25.92 | 2023 | Diacomit |
| Vertex Pharmaceuticals Incorporated | $24.35 | 2025 | |
| Zogenix INC. | $22.03 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.39 | 2024 | |
| Livanova USA, INC. | $21.20 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $20.45 | 2021 | |
| Tg Therapeutics, INC. | $19.94 | 2025 | |
| Pfizer INC. | $17.98 | 2025 | |
| Biomarin Pharmaceutical INC. | $17.23 | 2022 | |
| Travere Therapeutics, INC. | $6.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.